Our top pick for
Aphria Inc is a drug manufacturers—specialty & generic business based in the US. Aphria shares (APHA) are listed on the NASDAQ and all prices are listed in US Dollars. Aphria employs 1,200 staff and has a market cap (total outstanding shares value) of USD$1.2 billion.
|52-week range||USD$1.95 - USD$6|
|50-day moving average||USD$4.5829|
|200-day moving average||USD$4.0609|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.299|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-17)||-100.00%|
|1 month (2020-08-26)||-100.00%|
|3 months (2020-06-26)||-100.00%|
|6 months (2020-03-26)||-100.00%|
|1 year (2019-09-26)||-100.00%|
|2 years (2018-09-26)||-100.00%|
|3 years (2017-09-26)||-100.00%|
|5 years (2015-09-23)||N/A|
Valuing Aphria stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Aphria's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Aphria's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 57x. In other words, Aphria shares trade at around 57x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
|Gross profit TTM||USD$191 million|
|Return on assets TTM||0.07%|
|Return on equity TTM||-4.74%|
|Market capitalisation||USD$1.2 billion|
TTM: trailing 12 months
There are currently 39.2 million Aphria shares held short by investors – that's known as Aphria's "short interest". This figure is 4.3% down from 40.9 million last month.
There are a few different ways that this level of interest in shorting Aphria shares can be evaluated.
Aphria's "short interest ratio" (SIR) is the quantity of Aphria shares currently shorted divided by the average quantity of Aphria shares traded daily (recently around 4.8 million). Aphria's SIR currently stands at 8.12. In other words for every 100,000 Aphria shares traded daily on the market, roughly 8120 shares are currently held short.
However Aphria's short interest can also be evaluated against the total number of Aphria shares, or, against the total number of tradable Aphria shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aphria's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Aphria shares in existence, roughly 140 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Aphria shares, roughly 0 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Aphria.
Find out more about how you can short Aphria stock.
We're not expecting Aphria to pay a dividend over the next 12 months.
Over the last 12 months, Aphria's shares have ranged in value from as little as $1.95 up to $6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aphria's is 2.0203. This would suggest that Aphria's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.